enlightenbio  Blog

New Report – Analytics of the Microbiome Landscape

Palo Alto, CA, October 19, 2020 – The “Analytics of the Microbiome Landscape” report has been added to the enlightenbio LLC offering. This new report provides insights into the transformational microbiome landscape. It is a rigorous assessment of industry trends with detailed segmentation across publications, grants, clinical trials, and startup funding activities and it showcases the most innovative emerging companies and academics with activities in the areas of research and therapeutic interventions involving the microbiome. The report is based on real world evidence that will drive actionable insights.

 While this report does not intend to provide direct recommendations on commercial offerings, the detailed analytics provides an insightful review to help investors and commercial entities (sales, marketing, and strategy teams) choose the best partner for success.

For a limited time only, apply Promo Code MICROBIOMEREPORT15OFF and get 15% off when purchasing the report or any report module – valid until November 20, 2020.

Download Table of Contents to learn more about the report specifics

The reports allows to unearth data driven intelligence to power marketing campaigns, fundraising, investor pitches, and business/corporate development activities by tapping into premium data sources that leverage natural language processing (NLP) and relational search paradigm to uncover relevant data points, all in one package.

Report Content

This report covers all aspects of the analytics of the microbiome landscape. Over 40,000 scientific publications, over 3,000 grants, and hundreds of trials and funding activities have been analyzed.

Keywords commonly associated with the microbiome linked to NLP were used to extract information from marquee databases (e.g., Dimensions from Digital Science and Global Data) as well as the vast information provided on the World Wide Web (e.g., CB Insights, Crunchbase, LinkedIn, Pitchbook, and Polsky Microbiome Venture Funding data to name a few) associated with publications, academic grants, clinical trials, and startup funding activities. These databases span many sources, have a wide geographic coverage and use precise search algorithms. This resulting data has been curated and quality controlled to ensure accurate representation.

The report consists of four major modules, a publications, clinical trials, grants, and startup funding activities module – each module can be purchased separately.

Publications are a direct reflection of ongoing research trends in any given field, or in other words, publications are an indicator of market demand: This module uncovers intelligence of the transformational microbiome landscape captured from publications over several years (2011-2019). Publication trends monitored include: top microbiome researchers; funding agencies with the most publications; and distribution by region, country, and disease area.

Analysis of ongoing clinical trials is crucial for understanding the recognized impact of the microbiome on human health & disease: This module provides insights into the analytics associated with microbiome-focused clinical trials captured over several years (2015-2020) and includes: clinical trial distribution by country, phase, & sponsor type; top sponsors and companies; top therapy areas, indications, endpoints classifications, and interventions.

Research grants awarded are a close representation of the market opportunities in the academic sector: This module provides insights into the analytics associated with research grant dollars awarded in the scientific microbiome community over several years (2011-2019). Grant trends captured include: funding distribution by country and disease area; funding agencies with the most grants; and top funded institutions and researchers.

Understanding startup funding activities across human health, agriculture, and the food/beverages sectors is critical: This module captures the analytics associated with startup funding activities over several years (2015-2020) and includes: investments in microbiome companies; distribution by geographies, funder types, and funding rounds; as well as allocation by industry and disease area, top investors and top companies that have raised the most capital.

This full report is a Tableau Workbook with 20 tabs which requires to download the free version of the Tableau Reader to view the data.

Companies, organizations, and agencies mentioned in the report: 4D Pharma Plc, Adare Pharmaceuticals, Afineur, Albert Einstein College of Medicine (AECOM), Arranta Bio, AstraZeneca Plc, Baylor College of Medicine, Biotechnology and Biological Sciences Research Council (BBSRC), Canadian Institutes of Health Research (CIHR), Chinese Academy of Sciences (CAS), Computomics, Coordenação de Aperfeicoamento de Pessoal de Nível Superior (CAPES), CosmosID, Directorate for Biological Sciences (NSF BIO), Enterome Bioscience SA, European Commission (EC), European Research Council (ERC),  Evolve BioSystems, Finch Therapeutics, Flanders Institute for Biotechnology (VIB), German Research Foundation (DFG), Harvard University, Icahn School of Medicine at Mount Sinai (SMMS), Imperial College London, Indigo Ag, Intralytix, Japan Society for the Promotion of Science (JSPS), Joyn Bio, Kaleido Biosciences Inc, Karius, Karolinska Institute (KI), King’s College London (KCL), Lodo Therapeutics, Massachusetts General Hospital (MGH), Medical Research Council (MRC), Microbiome Diagnostics Partners, Ministry of Economy, Industry and Competitiveness (MINECO), Ministry of Science and Technology of the People’s Republic of China (MOST), National Agency for Research (ANR), National Cancer Institute (NCI), National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS), National Center for Advancing Translational Sciences (NCATS), National Council for Scientific and Technological Development (CNPq), National Heart Lung and Blood Institute (NHLBI), National Heart Lung and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute for Health Research (NIHR), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Food and Agriculture (NIFA), National Institute of General Medical Sciences (NIGMS), National Institute of General Medical Sciences (NIGMS), National Natural Science Foundation of China (NSFC), National Research Foundation of Korea (NRF), Natural Sciences and Engineering Research Council (NSERC), Nubiyota LLC, Nuritas, Office of the Director (OD), Perfect Day, Queen’s University Belfast (QUB), Seres Therapeutics Inc, Summit Therapeutics Plc, Swiss National Science Foundation (SNF), Synlogic Inc, TargEDys, United States Department of Agriculture (USDA), University of Alabama at Birmingham (UAB), University of California, Los Angeles (UCLA), University of California, San Diego (UCSD), University of Cambridge, University of Chicago (UC), University of Copenhagen (UCPH), University of Maryland, Baltimore (UMAB), University of Michigan (UM), University of North Carolina at Chapel Hill (UNC), University of Pittsburgh, Vedanta Biosciences Inc, Viome, Vyome Therapeutics, Washington University in St. Louis (WUSTL), and Wellcome Trust (WT).

For more information contact info@enlightenbio.com or visit our website, enlightenbio.com.

Press Release


%d bloggers like this: